摘要
目的:探讨阿瑞匹坦用于含顺铂的两药方案治疗Ⅳ期肺癌所引起的恶心、呕吐(CINV)的止吐作用和安全性。方法:Ⅳ期肺癌病例42例,均采用含顺铂的两药方案化疗。第一疗程化疗采用格拉司琼、地塞米松等标准止吐方案,但止吐效果不理想,第二疗程加用阿瑞匹坦,采用自体比较方法评价阿瑞匹坦的用药效果及安全性。结果:第二疗程患者止吐效果显著好于第一疗程,两个疗程患者止吐效果间比较差异具有统计学意义(P<0.01)。第二疗程患者急性恶心、急性呕吐、延迟恶心和延迟呕吐的发生率均显著低于第一疗程,两个疗程间数据比较差异具有统计学意义(P<0.01)。第二疗程患者腹泻、头晕、头痛、便秘、腹胀、失眠和皮疹的发生率比较差异无统计学意义(P>0.05),但疲倦和口干发生率显著高于第一疗程(P<0.05),说明疲倦和口干可能为阿瑞匹坦最常见的不良反应。结论:对标准止吐方案治疗后无显著效果的Ⅳ期肺癌化疗患者,加用阿瑞匹坦可达到较好的止吐效果,尤其对延迟恶心、呕吐效果显著。且用药安全性好,适合于临床应用。
Objective： To investigate antiemetic effect and safety of aprepitant for advanced lung cancer cisplatin chemotherapy drugs induced nausea and vomiting（ CINV）. Methods： All 42 lung cancer patients Ⅳ period were given two-drug regimen containing cisplatin,the first course of chemotherapy were given granisetron,dexamethasone,and other standard antiemetic regimen. But antiemetic effect was not ideal,and the second medications plus aprepitant. The effect of aprepitant treatment and safety was evaluated. Results： The antiemetic effect of the second course was significantly higher than the first course,the difference of antiemetic effect in patients of two courses was statistically significant（ P〈0. 01）. The incidence of acute nausea,vomiting,acute,delayed nausea and vomiting of the second course were significantly lower than the first course（ P〈0. 01）. The incidence of diarrhea,dizziness,headache,constipation,bloating,insomnia and rashes of the second course had no significant difference（ P〉0. 05）. But the incidence of fatigue and dry mouth were significantly higher than the first course（ P〈0. 05）,indicating fatigue and dry mouth may be the most common adverse reactions to aprepitant. Conclusion： When patients with advanced lung cancer chemotherapy antiemetic regimen of standard had no significant effect of treatment,plus aprepitant antiemetic CINV can achieve better results. The effect for delayed nausea and vomiting is significant,and safe,suitable for clinical application.
出处
《现代肿瘤医学》
CAS
2015年第23期3421-3423,共3页
Journal of Modern Oncology
基金
北京市卫生局创新支持计划(编号:20130618)
